Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic

COVID-19 Global Rheumatology Alliance

doi:10.1007/s11845-022-03265-7

Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic

COVID-19 Global Rheumatology Alliance

Inflammation Biology

St. James's Hospital
Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, and Zuyderland MC, Heerlen, the Netherlands.
Department of Orthodontics, Queen Mary's Hospital, Sidcup, King's College Hospital NHS Foundation Trust/King's College, London, UK.
Centre for RMDs
1Department of Hepatology, Imperial College London, London, UK. 2Institute of Liver Studies at King's College School of Medicine at King's College Hospital, London, UK. 3Institute of Human Health and Performance, University College London, London, UK. 4Department of Asthma Allergy and Lung Biology, King's College London, London, UK. 5Division of Critical Care Medicine, University of Alberta, Edmonton, Canada.
University of Nicosia
St Vincent's University Hospital
Mater Misericordiae University Hospital
University Dental School & Hospital/University College Cork, Wilton, Cork, Ireland. Electronic address: [email protected].
Galway Clinic
University Hospitals Limerick
Department of Anaesthesia, Galway University Hospitals, Galway, Ireland.
Division of Neurology, Beaumont Hospital, Dublin 9, Ireland
Trinity College Dublin
Blackrock Clinic Ireland
Queensland Brain Institute, University of Queensland, Brisbane, QLD 4072, Australia; University of Queensland Diamantina Institute, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia;
Department of Medicine, Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA, 02118, USA.
University of Otago Wellington

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

20 Downloads (Pure)

Abstract

BACKGROUND: Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding risk mitigation.

AIM: To describe COVID-19 outcomes for people with RMD in Ireland over the first 2 years of the pandemic.

METHODS: Data entered into the C19-GRA provider registry from Ireland between 24th March 2020 and 31st March 2022 were analysed. Differences in the likelihood of hospitalisation and mortality according to demographic and clinical variables were investigated.

RESULTS: Of 237 cases included, 59.9% were female, 95 (41.3%) were hospitalised, and 22 (9.3%) died. Hospitalisation was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular and pulmonary disease, and cancer. Hospitalisation was less frequent in people with inflammatory arthritis and conventional synthetic or biologic disease-modifying antirheumatic drug use. Hospitalisation had a U-shaped relationship with disease activity, being more common in both high disease activity and remission. Mortality was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular disease, pulmonary disease, and obesity. Inflammatory arthritis was less frequent in those who died.

CONCLUSION: Hospitalisation or death were more frequently experienced by RMD patients with increasing age, certain comorbidities including potentially modifiable ones, and certain medications and diagnoses amongst other factors. These are important 'indicators' that can help risk-stratify and inform the management of RMD patients.

Original language	English
Pages (from-to)	2495-2500
Number of pages	6
Journal	Irish Journal of Medical Science
Volume	192
Issue number	5
Early online date	9 Jan 2023
DOIs	https://doi.org/10.1007/s11845-022-03265-7
Publication status	Published - Oct 2023

Keywords

Humans
Female
Male
Ireland/epidemiology
Pandemics
Glucocorticoids
COVID-19/epidemiology
Musculoskeletal Diseases/epidemiology
Gout

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11845-022-03265-7Licence: CC BY

Conway_COVID_2023Final published version, 619 KBLicence: CC BY

Cite this

@article{72cf0ac86bc94bcb9daa8492bd0b2072,

title = "Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic",

abstract = "BACKGROUND: Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding risk mitigation.AIM: To describe COVID-19 outcomes for people with RMD in Ireland over the first 2 years of the pandemic.METHODS: Data entered into the C19-GRA provider registry from Ireland between 24th March 2020 and 31st March 2022 were analysed. Differences in the likelihood of hospitalisation and mortality according to demographic and clinical variables were investigated.RESULTS: Of 237 cases included, 59.9% were female, 95 (41.3%) were hospitalised, and 22 (9.3%) died. Hospitalisation was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular and pulmonary disease, and cancer. Hospitalisation was less frequent in people with inflammatory arthritis and conventional synthetic or biologic disease-modifying antirheumatic drug use. Hospitalisation had a U-shaped relationship with disease activity, being more common in both high disease activity and remission. Mortality was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular disease, pulmonary disease, and obesity. Inflammatory arthritis was less frequent in those who died.CONCLUSION: Hospitalisation or death were more frequently experienced by RMD patients with increasing age, certain comorbidities including potentially modifiable ones, and certain medications and diagnoses amongst other factors. These are important 'indicators' that can help risk-stratify and inform the management of RMD patients.",

keywords = "Humans, Female, Male, Ireland/epidemiology, Pandemics, Glucocorticoids, COVID-19/epidemiology, Musculoskeletal Diseases/epidemiology, Gout",

author = "{COVID-19 Global Rheumatology Alliance} and Richard Conway and Elena Nikiphorou and Demetriou, {Christiana A} and Candice Low and Kelly Leamy and Ryan, {John G} and Ronan Kavanagh and Fraser, {Alexander D} and Carey, {John J} and Paul O'Connell and Flood, {Rachael M} and Mullan, {Ronan H} and Kane, {David J} and Frances Stafford and Robinson, {Philip C} and Liew, {Jean W} and Rebecca Grainger and McCarthy, {Geraldine M}",

note = "Funding Information: The authors would like to thank all rheumatology providers who entered data into the registry. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = oct,

doi = "10.1007/s11845-022-03265-7",

language = "English",

volume = "192",

pages = "2495--2500",

journal = "Irish Journal of Medical Science",

issn = "0021-1265",

publisher = "Psychological Society of Ireland",

number = "5",

}

TY - JOUR

T1 - Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic

AU - COVID-19 Global Rheumatology Alliance

AU - Conway, Richard

AU - Nikiphorou, Elena

AU - Demetriou, Christiana A

AU - Low, Candice

AU - Leamy, Kelly

AU - Ryan, John G

AU - Kavanagh, Ronan

AU - Fraser, Alexander D

AU - Carey, John J

AU - O'Connell, Paul

AU - Flood, Rachael M

AU - Mullan, Ronan H

AU - Kane, David J

AU - Stafford, Frances

AU - Robinson, Philip C

AU - Liew, Jean W

AU - Grainger, Rebecca

AU - McCarthy, Geraldine M

PY - 2023/10

Y1 - 2023/10

N2 - BACKGROUND: Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding risk mitigation.AIM: To describe COVID-19 outcomes for people with RMD in Ireland over the first 2 years of the pandemic.METHODS: Data entered into the C19-GRA provider registry from Ireland between 24th March 2020 and 31st March 2022 were analysed. Differences in the likelihood of hospitalisation and mortality according to demographic and clinical variables were investigated.RESULTS: Of 237 cases included, 59.9% were female, 95 (41.3%) were hospitalised, and 22 (9.3%) died. Hospitalisation was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular and pulmonary disease, and cancer. Hospitalisation was less frequent in people with inflammatory arthritis and conventional synthetic or biologic disease-modifying antirheumatic drug use. Hospitalisation had a U-shaped relationship with disease activity, being more common in both high disease activity and remission. Mortality was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular disease, pulmonary disease, and obesity. Inflammatory arthritis was less frequent in those who died.CONCLUSION: Hospitalisation or death were more frequently experienced by RMD patients with increasing age, certain comorbidities including potentially modifiable ones, and certain medications and diagnoses amongst other factors. These are important 'indicators' that can help risk-stratify and inform the management of RMD patients.

AB - BACKGROUND: Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding risk mitigation.AIM: To describe COVID-19 outcomes for people with RMD in Ireland over the first 2 years of the pandemic.METHODS: Data entered into the C19-GRA provider registry from Ireland between 24th March 2020 and 31st March 2022 were analysed. Differences in the likelihood of hospitalisation and mortality according to demographic and clinical variables were investigated.RESULTS: Of 237 cases included, 59.9% were female, 95 (41.3%) were hospitalised, and 22 (9.3%) died. Hospitalisation was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular and pulmonary disease, and cancer. Hospitalisation was less frequent in people with inflammatory arthritis and conventional synthetic or biologic disease-modifying antirheumatic drug use. Hospitalisation had a U-shaped relationship with disease activity, being more common in both high disease activity and remission. Mortality was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular disease, pulmonary disease, and obesity. Inflammatory arthritis was less frequent in those who died.CONCLUSION: Hospitalisation or death were more frequently experienced by RMD patients with increasing age, certain comorbidities including potentially modifiable ones, and certain medications and diagnoses amongst other factors. These are important 'indicators' that can help risk-stratify and inform the management of RMD patients.

KW - Humans

KW - Female

KW - Male

KW - Ireland/epidemiology

KW - Pandemics

KW - Glucocorticoids

KW - COVID-19/epidemiology

KW - Musculoskeletal Diseases/epidemiology

KW - Gout

UR - http://www.scopus.com/inward/record.url?scp=85146011102&partnerID=8YFLogxK

U2 - 10.1007/s11845-022-03265-7

DO - 10.1007/s11845-022-03265-7

M3 - Article

C2 - 36622628

SN - 0021-1265

VL - 192

SP - 2495

EP - 2500

JO - Irish Journal of Medical Science

JF - Irish Journal of Medical Science

IS - 5

ER -

Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this